Eidos Therapeutics to Present at the Leerink Partners Roundtable Series: Rare Disease & Oncology
September 25 2018 - 8:00AM
Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX) today announced that
management will participate in a fireside chat at the Leerink
Partners Roundtable Series: Rare Disease & Oncology on Tuesday,
October 2, 2018 at 3:30 p.m. ET. The conference will be held in New
York, NY.
A live audio webcast of the presentation can be accessed through
the Events & Presentations section of the company's website at
ir.eidostx.com. An archived replay of the webcast will be available
on the company's website for 90 days following the live
presentation.
About Eidos Therapeutics
Eidos Therapeutics is a clinical stage biopharmaceutical company
focused on addressing the large and growing unmet need in diseases
caused by transthyretin, or TTR, amyloidosis, or ATTR. We seek to
treat this well-defined family of diseases at their collective
source by stabilizing TTR. Our product candidate, AG10, an
orally-administered small molecule designed to potently stabilize
TTR, is a potentially best-in-class treatment aiming to halt the
progression of ATTR diseases.
Founded in 2013, Eidos is led by a team of industry veterans who
are responsible for developing over 30 molecules through IND
applications and more than 10 approved drugs. Together with
patients and physicians, we aim to bring a safe, effective and
disease-modifying treatment for ATTR to market as quickly as
possible.
Media Contact:
Carolyn Hawley, Canale Communications, (619) 849-5382,
carolyn@canalecomm.com
For Investors
Alex Gray, Burns McClellan, (212) 213-0006,
agray@burnsmc.com
Eidos Therapeutics (NASDAQ:EIDX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Eidos Therapeutics (NASDAQ:EIDX)
Historical Stock Chart
From Apr 2023 to Apr 2024